Connection

Kenneth Tew to Estramustine

This is a "connection" page, showing publications Kenneth Tew has written about Estramustine.
Connection Strength

2.597
  1. Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies. Biomed Pharmacother. 2012 Sep; 66(6):403-8.
    View in: PubMed
    Score: 0.396
  2. Evaluation of lipophilins as determinants of tumor cell response to estramustine. J Pharmacol Exp Ther. 2005 Dec; 315(3):1158-62.
    View in: PubMed
    Score: 0.246
  3. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. 1998 Apr 01; 58(7):1332-7.
    View in: PubMed
    Score: 0.147
  4. Interaction of estramustine with tubulin isotypes. Biochemistry. 1997 Jan 28; 36(4):871-8.
    View in: PubMed
    Score: 0.136
  5. Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins. Cancer. 1995 May 15; 75(10):2597-604.
    View in: PubMed
    Score: 0.121
  6. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol. 1994 Nov; 46(5):866-72.
    View in: PubMed
    Score: 0.116
  7. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst. 1994 May 04; 86(9):688-94.
    View in: PubMed
    Score: 0.112
  8. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther. 1992 Dec; 56(3):323-39.
    View in: PubMed
    Score: 0.102
  9. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype. Br J Cancer. 1991 Aug; 64(2):267-73.
    View in: PubMed
    Score: 0.093
  10. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells. Eur J Cell Biol. 1991 Apr; 54(2):268-76.
    View in: PubMed
    Score: 0.091
  11. Mechanism based chemotherapy for prostate cancer. Cancer Surv. 1991; 11:239-54.
    View in: PubMed
    Score: 0.089
  12. Intracellular effects of estramustine (Estracyt/Emcyt). Prog Clin Biol Res. 1989; 303:169-75.
    View in: PubMed
    Score: 0.078
  13. Estramustine--a nitrogen mustard/steroid with antimicrotubule activity. Pharmacol Ther. 1989; 43(3):299-319.
    View in: PubMed
    Score: 0.078
  14. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci. 1988 Mar; 89 ( Pt 3):331-42.
    View in: PubMed
    Score: 0.073
  15. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res. 1987; 15(3):155-60.
    View in: PubMed
    Score: 0.068
  16. Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine. Cancer Treat Rep. 1986 Jun; 70(6):715-20.
    View in: PubMed
    Score: 0.065
  17. Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. Proc Natl Acad Sci U S A. 1985 Dec; 82(24):8483-7.
    View in: PubMed
    Score: 0.063
  18. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res. 1985 Aug; 45(8):3891-7.
    View in: PubMed
    Score: 0.061
  19. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology. 1984 Jun; 23(6 Suppl):28-33.
    View in: PubMed
    Score: 0.056
  20. Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochim Biophys Acta. 2004 Apr 16; 1678(1):22-32.
    View in: PubMed
    Score: 0.056
  21. The mechanism of action of estramustine. Semin Oncol. 1983 Sep; 10(3 Suppl 3):21-6.
    View in: PubMed
    Score: 0.054
  22. Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets. Mol Pharmacol. 1983 Sep; 24(2):324-8.
    View in: PubMed
    Score: 0.054
  23. Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res. 2001 Apr 15; 61(8):3339-47.
    View in: PubMed
    Score: 0.045
  24. Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells. Int J Cancer. 1998 Aug 12; 77(4):626-31.
    View in: PubMed
    Score: 0.038
  25. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem Pharmacol. 1998 Feb 01; 55(3):325-31.
    View in: PubMed
    Score: 0.036
  26. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996 Jun 01; 56(11):2584-9.
    View in: PubMed
    Score: 0.032
  27. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992 Aug 15; 52(16):4433-40.
    View in: PubMed
    Score: 0.025
  28. Molecular conformation of estramustine and two analogues. Mol Pharmacol. 1992 Mar; 41(3):569-76.
    View in: PubMed
    Score: 0.024
  29. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol. 1988 Dec; 107(6 Pt 2):2647-56.
    View in: PubMed
    Score: 0.019
  30. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine. Anticancer Res. 1987 Nov-Dec; 7(6):1165-71.
    View in: PubMed
    Score: 0.018
  31. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992 Nov; 10(11):1754-61.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.